Anne Li May 6th, 2017
A new study identifies a potential test that may help select patients for whom combination therapy could be most effective. Researchers have been trying to understand why up to 85 percent of women experience recurrence of high-grade serous ovarian cancer — the most common subtype of ovarian cancer — after standard treatment with the chemotherapy drug carboplatin.
See original article at: https://www.sciencedaily.com/releases/2017/05/170501184327.htm
